Skip to main content

For Health Care Providers

How can providers prescribe COVID-19 therapeutics to patients?

Clinicians caring for COVID-19 patients should be aware of the availability of these important life-saving medications and consider use when clinically indicated. When prescribing COVID-19 treatments, health care providers can use the following tools:

For an overview of mild to moderate COVID-19 outpatient therapies:

For the management of Paxlovid drug-drug-interactions:

For COVID-19 oral antiviral medications standard prescriptions:

 

To see what locations currently have COVID-19 therapeutics.

What is Test to Treat?

The Test to Treat program is a nationwide initiative launched by the federal government to ensure rapid access to no-cost COVID-19 oral medications for individuals who have tested positive for COVID–19, who are experiencing mild to moderate symptoms, and who are at high risk for severe disease including hospitalization and/or death. Test to Treat sites will provide COVID-19 tests, determine eligibility of COVID-19 patients to receive COVID-19 therapy, and prescribe medication that patients can fill on-site or at affiliated pharmacies.

What Is Antiviral Medication?

Antiviral medication is a treatment that kills a virus or suppresses its ability to replicate and, hence, inhibits its capability to multiply and reproduce. Vaccinations remain the best way to protect a person from COVID, and are a preventative measure to reduce severity of illness and risk of hospitalization or, even, death. Antivirals are prescribed after a person has tested positive for COVID-19 and within 5 days of symptom onset. Talk to a provider about your eligibility for antiviral treatment.

What Are Monoclonal Antibody Therapies?

Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance or mimic the immune system's attack on cells. Monoclonal antibodies are designed to block viral attachment and entry into human cells, thus neutralizing the virus. It is designed to limit viral replication and may be effective for the treatment of COVID-19 in patients who are at high risk for progressing to severe COVID-19 and/or hospitalization.

Monoclonal antibody treatment is for people who have tested positive for COVID-19 and have mild to moderate symptoms. When administered to non-hospitalized patients as soon as possible after positive viral testing for SARS-CoV-2 and within 7 days of symptom onset, monoclonal antibodies may reduce viral load, symptoms, and risk of hospitalizations and emergency room visits associated with COVID-19. Information reported by the manufacturers to the food and drug administration indicates that among high-risk symptomatic individuals, there is a 70% reduction in hospitalizations and deaths.

Bebtelovimab is currently the only authorized monoclonal antibody therapy given the prevalence of the Omicron BA.2 sub-variant.